• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

522 Postmarket Surveillance Studies Database

  • Print
  • Share
  • E-mail
The FDA has the authority to require device manufacturers to perform postmarket surveillance under Section 522 of the Food, Drugs and Cosmetics (FD&C) Act, when questions are identified for devices that meet the statutory criteria. This database contains information about 522 Postmarket Surveillance Studies that have been required. This database allows you to search information about the postmarket surveillance requirements by manufacturer or device.

Learn more...

  To search for Manufacturer beginning with a specific letter, select that letter

Time to Revision and Explant Analysis

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
522 Number / Requirement Number PS110003 / PSS001
Date Original Plan Accepted 01/13/2012
Date Current Plan Accepted 11/08/2019
Study Name Time to Revision and Explant Analysis
Device Name Patient-fitted tmj reconstruction prosthesis system
Root Document Number P980052  Q220196 
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source Sponsor Registry
Comparison Group No Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives Objective 1: Survival Analysis- Prospective Cohort. To determine the survival rate for revision and/or removal of TMJ Concepts implants and use this data to determine factors that affect this survival during three years of follow-up. This will answer questions 1-3 and question 5b. Objective 2: Reason for Failure Analysis-cross-sectional study. To determine the reasons for TMJ implant revisions and removals among patients who have had TMJ Concepts implants. This will answer question 4. Objective 3: Explant Analysis. To determine the specific modes and causes of failure based on an analysis of all reasonably available explanted retrieved TMJ Concepts devices. This will answer question 5a.
Study Population 18 to 21 yrs; Adult 21+
Sample Size 672 patients
Key Study Endpoints 1. Survival Analysis: Revision or removal at three years of follow-up; Revision or removal for subgroups of patients. 2. Reason for failure analysis: Reasons for initial and subsequent revision or removal. 3. Explant Analysis; TMJ implant failure.
Follow-up Visits and Length of Follow-up FU Visits: Annually; Length of FU: 3 years

Time to Revision and Explant Analysis Reporting Schedule

Reporting Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
6 month report 10/01/2013 11/13/2013 Overdue/Received
12 month report 04/01/2014 03/31/2014 On Time
18 month report 09/30/2014 09/30/2014 On Time
2 year report 04/01/2015 04/02/2015 Overdue/Received
3 year report 04/01/2016 04/04/2016 Overdue/Received
4 year report 04/03/2017 06/12/2017 Overdue/Received
5 year report 04/01/2018 03/12/2019 On Time
final report 01/20/2020 01/21/2020 Overdue/Received
complete final report 05/08/2024 05/08/2024 On Time

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources